Periodic Reporting for period 1 - ClarifyLupus (Launching the Breakthrough in Lupus Diagnostics)
Reporting period: 2019-03-01 to 2019-08-31
Our solution, ClarifyLupus, is a test for Lupus diagnosis that consists of the detection and quantification of the Lupus-specific biomarker by mass spectrometry. Whilst the state-of-the-art existing solutions focus on the detection of antibodies and have been associated with low specificity, ClarifyLupus relies on monitoring a lupus-specific event, thereby offering less false positives/negatives.
Our research and tests have proven the Lupus-specificity of our biomarker by analysing blood samples from Lupus patients and other confounding diseases, and healthy groups. In fact, our biomarker was absent from blood samples of healthy volunteers and rheumatoid arthritis patients analysed and were identified in 90% of lupus patients analysed enabling early lupus diagnosis, with less false positives and negatives, improving performance over currently available tests. Although our competitors are conducting research on Lupus biomarker discovery, they are all focused on autoantibodies and immune response biomarkers identification that are highly unspecific.
ClarifyLupus allows Lupus patients to ensure on-time and easy diagnosis. A proof-of-concept is at its early stage where a large cohort of lupus patients, confounding diseases cohorts and healthy groups are currently being recruited, for determining accurately the specificity of our biomarker.